Severe, long-standing DME with cystoid changes, subretinal detachment, and high inflammatory cytokine burden tends to respond ...

STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

STOCKHOLM — Trial results are demonstrating positive findings for a single intravitreal injection gene therapy for patients with neovascular age-related macular degeneration (nAMD) who previously ...

Susvimo is an FDA-approved eye implant for diabetic macular edema that may reduce monthly injections to just two treatments a ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — When administering anti-VEGF treatments to patients with wet age-related macular degeneration, ...

Please provide your email address to receive an email when new articles are posted on . Visual acuity increased by 3 letters on average at year 1. By year 6, annual decreases led to a net loss of 4.6 ...

Migaldendranib (MGB) is a new class of targeted nanomedicine for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) with a novel mechanism of action ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...

New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the "port" ...

Anti-VEGF drugs are associated with kidney injury for some patients, but no particular anti-VEGF has a stronger association than any others. The risk of kidney failure for people who receive ...